Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 18/20 | 1.00 |
| ▸ | MAOA | P21397 | 16/20 | 1.00 |
| ▸ | MAOB | P27338 | 13/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 6/20 | 1.00 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813993 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL2557921 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL21471753 | 1.00 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL15789127 | 0.98 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL15789125 | 0.98 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL17003579 | 0.94 | MAOA (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL17003580 | 0.94 | MAOA (1.00) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL17003042 | 0.92 | MAOA (0.97) | KDM1AMAOAMAOBRCOR1KDM1B | |
| Hydrochloric Acid SCHEMBL17003041 | 0.92 | MAOA (0.97) | KDM1AMAOAMAOBRCOR1KDM1B | |
| SCHEMBL17287978 | 0.91 | KDM1A (1.00) | KDM1AMAOAMAOBRCOR1KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-17 | — | — | US | disclosed |
| EP-2743256-B1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9920047-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9920047-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-20 | — | — | US | disclosed |
| US-9751885-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9751885-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-05 | — | — | US | disclosed |
| US-9718814-B2 | Cyclopropanamine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-9278931-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-9278931-B2 | Cyclopropaneamine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162853-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 493/4885MAOB 495/4885 |
| US-20160130215-A1 | CYCLOPROPANEAMINE COMPOUND | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOA 101/4885MAOB 90/4885 |
| US-20210179603-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 493/4885MAOB 495/4885 |
| US-20150266881-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | BHMT, HNMT, KDM1A | KDM1A 3/4885MAOA 21/4885MAOB 27/4885 |
| US-20140228405-A1 | CYCLOPROPANEAMINE COMPOUND | KDM1A, KDM1B, KDM3A | KDM1A 1/4885MAOA 101/4885MAOB 90/4885 |
| US-10414761-B2 | Cyclopropanamine compound and use thereof | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 493/4885MAOB 495/4885 |
| US-20150291577-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | KDM1A 1/4885MAOA 493/4885MAOB 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.